Trial Profile
A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CE 224535 (Primary)
- Indications Osteoarthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 16 Nov 2008 New trial record.